Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis
NCT02337205
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
29
Enrollment
INDUSTRY
Sponsor class
Conditions
Actinic Keratosis
Interventions
DRUG:
KX2-391 Ointment
Sponsor
Athenex, Inc.